Sharin E. Roth

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Jeffrey L. Woodhead, William J. Brock, Sharin E. Roth et al. · Toxicological Sciences · 2016 · 89 citations · Full text

Immunology, Pharmacotherapy, Evaluate Putative Mechanisms +20

Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach

Merrie Mosedale, Yunjung Kim, William J. Brock et al. · Toxicological Sciences · 2016 · 52 citations · Full text

Bile Acid Homeostasis, Immunology, Pathology +23

miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model

Merrie Mosedale, J. Scott Eaddy, O. Joseph Trask et al. · Toxicological Sciences · 2017 · 49 citations · Full text

Immunotoxicology, Plasma Cmax, Idili Drug Tolvaptan +25

Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials

David Alpers, James H. Lewis, Christine M. Hunt et al. · American Journal of Kidney Diseases · 2022 · 32 citations · Full text

Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease

Salim S. Hayek, Douglas Landsittel, Changli Wei et al. · Journal of the American Society of Nephrology · 2019 · 29 citations · Full text